BACKGROUND:Inhaled nitric oxide improves gas exchange, decreases pulmonary vascular lability, and reduces pulmonary inflammation. We hypothesized that the use of inhaled nitric oxide would decrease the incidence of chronic lung disease and death in premature infants with the respiratory distress syndrome. METHODS: We conducted a randomized, double-blind, placebo-controlled study of the effect of inhaled nitric oxide during the first week of life on the incidence of chronic lung disease and death in premature infants (less than 34 weeks' gestation) who were undergoingmechanical ventilationfor the respiratory distress syndrome. Infants were randomly assigned to receive inhaled nitric oxide (10 ppm on day 1, followed by 5 ppm for six days) or inhaled oxygen placebo for seven days. We further randomly assigned the infants in each group to receive intermittent mandatory or high-frequency oscillatory ventilation. RESULTS: A total of 207 premature infants were enrolled. In the group given inhaled nitric oxide, 51 infants (48.6 percent) died or had chronic lung disease, as compared with 65 infants (63.7 percent) in the placebo group (relative risk, 0.76; 95 percent confidence interval, 0.60 to 0.97; P=0.03). There was no significant difference between the nitric oxide and placebo groups in the overall incidence of intraventricular hemorrhage and periventricular leukomalacia (33.3 percent and 38.2 percent, respectively), but the group given inhaled nitric oxide had a lower incidence of severe intraventricular hemorrhage and periventricular leukomalacia (12.4 percent vs. 23.5 percent; relative risk, 0.53; 95 percent confidence interval, 0.28 to 0.98; P=0.04). The type of ventilation had no significant effect on the outcome. CONCLUSIONS: The use of inhaled nitric oxide in premature infants with the respiratory distress syndrome decreases the incidence of chronic lung disease and death. Copyright 2003 Massachusetts Medical Society
RCT Entities:
BACKGROUND: Inhaled nitric oxide improves gas exchange, decreases pulmonary vascular lability, and reduces pulmonary inflammation. We hypothesized that the use of inhaled nitric oxide would decrease the incidence of chronic lung disease and death in premature infants with the respiratory distress syndrome. METHODS: We conducted a randomized, double-blind, placebo-controlled study of the effect of inhaled nitric oxide during the first week of life on the incidence of chronic lung disease and death in premature infants (less than 34 weeks' gestation) who were undergoing mechanical ventilation for the respiratory distress syndrome. Infants were randomly assigned to receive inhaled nitric oxide (10 ppm on day 1, followed by 5 ppm for six days) or inhaled oxygen placebo for seven days. We further randomly assigned the infants in each group to receive intermittent mandatory or high-frequency oscillatory ventilation. RESULTS: A total of 207 premature infants were enrolled. In the group given inhaled nitric oxide, 51 infants (48.6 percent) died or had chronic lung disease, as compared with 65 infants (63.7 percent) in the placebo group (relative risk, 0.76; 95 percent confidence interval, 0.60 to 0.97; P=0.03). There was no significant difference between the nitric oxide and placebo groups in the overall incidence of intraventricular hemorrhage and periventricular leukomalacia (33.3 percent and 38.2 percent, respectively), but the group given inhaled nitric oxide had a lower incidence of severe intraventricular hemorrhage and periventricular leukomalacia (12.4 percent vs. 23.5 percent; relative risk, 0.53; 95 percent confidence interval, 0.28 to 0.98; P=0.04). The type of ventilation had no significant effect on the outcome. CONCLUSIONS: The use of inhaled nitric oxide in premature infants with the respiratory distress syndrome decreases the incidence of chronic lung disease and death. Copyright 2003 Massachusetts Medical Society
Authors: Lisa M Askie; Roberta A Ballard; Gary R Cutter; Carlo Dani; Diana Elbourne; David Field; Jean-Michel Hascoet; Anna Maria Hibbs; John P Kinsella; Jean-Christophe Mercier; Wade Rich; Michael D Schreiber; Pimol Srisuparp Wongsiridej; Nim V Subhedar; Krisa P Van Meurs; Merryn Voysey; Keith Barrington; Richard A Ehrenkranz; Neil N Finer Journal: Pediatrics Date: 2011-09-19 Impact factor: 7.124
Authors: George R Conahey; Gordon G Power; Andrew O Hopper; Michael H Terry; Laura S Kirby; Arlin B Blood Journal: Pediatr Res Date: 2008-10 Impact factor: 3.756
Authors: John P Kinsella; Gary R Cutter; Robin H Steinhorn; Leif D Nelin; William F Walsh; Neil N Finer; Steven H Abman Journal: J Pediatr Date: 2014-07-22 Impact factor: 4.406
Authors: Athena I Patrianakos-Hoobler; Michael E Msall; Jeremy D Marks; Dezheng Huo; Michael D Schreiber Journal: Pediatrics Date: 2009-07 Impact factor: 7.124
Authors: Athena I Patrianakos-Hoobler; Michael E Msall; Dezheng Huo; Jeremy D Marks; Susan Plesha-Troyke; Michael D Schreiber Journal: Dev Med Child Neurol Date: 2009-12-01 Impact factor: 5.449
Authors: Richard L Auten; Stanley N Mason; Mary H Whorton; William R Lampe; W Michael Foster; Ronald N Goldberg; Bo Li; Jonathan S Stamler; Kathryn M Auten Journal: Am J Respir Crit Care Med Date: 2007-05-03 Impact factor: 21.405